CIK 0001444192 · Non-accelerated filer<br>Smaller reporting company
Grace Therapeutics, Inc.
Sign in to watch- Ticker
- GRCE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 609-322-1602
- Business address
- 103 CARNEGIE CENTER, SUITE 300, PRINCETON, NJ, 08540
- Former names
- Acasti Pharma Inc.
- Open-market buys, last 90 days
- $814,975
- in 11 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$814,975. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-04-14 | Kumar Amresh VP Program Management | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2025-04-14 | Macdonald R. Loch Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2025-04-14 | DelAversano Robert J Principal Financial Officer | Grant or award · Stock Option (Right to Buy) | +20,130 | 20,130 | ||
| 2025-04-14 | Kohli Prashant Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +225,400 | 225,400 | ||
| 2025-04-14 | D'Andrea Carrie VP Clinical Operations | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2024-05-06 | D'Andrea Carrie VP Clinical Operations | Grant or award · Stock Options (Right to Buy) | +19,740 | 19,740 | ||
| 2024-05-06 | Kumar Amresh VP Program Management | Grant or award · Stock Options (Right to Buy) | +19,740 | 19,740 | ||
| 2024-05-06 | D'Andrea Carrie VP Program Management | Grant or award · Stock Options (Right to Buy) | +19,740 | 19,740 | ||
| 2024-05-06 | Kumar Amresh VP Clinical Operations | Grant or award · Stock Options (Right to Buy) | +19,740 | 19,740 | ||
| 2024-05-06 | Macdonald R. Loch Chief Medical Officer | Grant or award · Stock Options (Right to Buy) | +25,380 | 25,380 | ||
| 2024-05-06 | DelAversano Robert J Principal Financial Officer | Grant or award · Stock Options (Right to Buy) | +4,500 | 4,500 | ||
| 2024-05-06 | Kohli Prashant Chief Executive Officer | Grant or award · Stock Options (Right to Buy) | +128,770 | 128,770 | ||
| 2023-12-19 | Kavuru Vimal Director | Grant or award · Stock Options (Right to Buy) | +10,000 | 10,000 | ||
| 2023-12-19 | Kottayil George Director | Grant or award · Stock Options (Right to Buy) | +22,500 | 22,500 | ||
| 2023-12-19 | NEUGEBOREN EDWARD Director | Grant or award · Stock Options (Right to Buy) | +22,500 | 22,500 | ||
| 2023-12-19 | DAVIS A BRIAN Director | Grant or award · Stock Options (Right to Buy) | +22,500 | 22,500 | ||
| 2023-12-19 | Kohli Prashant Chief Executive Officer | Grant or award · Stock Options (Right to Buy) | +41,668 | 41,668 | ||
| 2023-09-25 | Kavuru Vimal Director | Purchase | +676,371 | $1.85 | $1.2M | 1,188,076 |
| 2023-09-25 | Kavuru Vimal Director | Purchase · Common Warrants (right to buy) | +422,732 | $0.13 | $53K | 422,732 |
| 2023-08-31 | Olds Donald Director | Purchase | +381 | $2.05 | $781 | 381 |
Page 3 of 5 · 83 trades